Myriad Genetics stock has recently seen its fair value price target rise slightly, moving from $8.29 to $8.38 per share. This change reflects subtle positive shifts in analyst sentiment. These ...
Clairity, Myriad Genetics, and MagView announce a joint collaboration in an effort to identify more women at high risk for breast cancer. zur Originalmeldung ...
BOSTON/SALT LAKE CITY/FULTON - Clairity, Myriad Genetics, Inc. (NASDAQ:MYGN), and MagView announced Tuesday a collaboration aimed at improving breast cancer risk assessment by integrating their ...
Clairity – developer of Clairity Breast, the first and only FDA-authorized offering to estimate a woman’s five-year breast cancer risk directly from a routine mammogram For the first time, clinicians ...
For the first time, clinicians and patients will have access to an integrated view of genotype (Myriad’s MyRisk with RiskScore test) and phenotype (Clairity Breast) through MagView’s Luminary Risk ...
BOSTON and SALT LAKE CITY and FULTON, Md., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Clairity, Myriad Genetics, Inc. (NASDAQ: MYGN), and MagView, today announced a joint collaboration in an effort to identify ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results